Final answer:
In the Phase 1 study of deucravacitinib, several Adverse Events (AEs) were identified, such as nausea, headache, diarrhea, and fatigue. Liver enzyme elevation, rash, and elevated blood pressure were also seen as less common but more serious AEs.
Step-by-step explanation:
In the Phase 1 study of deucravacitinib, several Adverse Events (AEs) were associated with the drug. Some of the common AEs observed in the study included nausea, headache, diarrhea, and fatigue. Other less common but more serious AEs included liver enzyme elevation, rash, and elevated blood pressure.